NEW YORK (Reuters Health) – The association between non-fatty alcoholic liver disease (NAFLD) and increased cardiovascular disease (CVD) risk is further increased with higher fibrosis stage, suggesting that NAFLD may be an independent risk factor for CVD morbidity and mortality,…

NEW YORK (Reuters Health) – An experimental, oral, once-daily, selective fatty acid synthase (FASN) inhibitor has shown promise for the treatment of non-alcoholic steatohepatitis (NASH), an aggressive form of nonalcoholic fatty liver disease (NAFLD). In a phase-2a clinical trial, the…